Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals, Inc. (AVIR) furnished its quarterly earnings press release for the three months ended September 30, 2025. The company reported this under Item 2.02 of Form 8-K on November 12, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The Item 2.02 information, including Exhibit 99.1, is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated into Securities Act or Exchange Act filings unless specifically referenced. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
Form 4 filing (24-Jun-2025) reveals that Atea Pharmaceuticals (AVIR) director Franklin M. Berger increased his ownership through equity-based compensation granted on 20-Jun-2025. A total of 29,600 previously issued restricted stock units (RSUs) vested and converted into common shares (Code M) at a $0.00 cost, lifting his direct holdings to 506,497 shares. Concurrently, Berger received 29,600 new RSUs that will vest at the next annual meeting or one-year anniversary, and 41,200 stock options with a $3.25 exercise price expiring 19-Jun-2035, vesting monthly over 12 months. No shares were sold. The transactions signal net insider accumulation while introducing modest potential dilution through the new RSUs and options.
Form 4 highlights for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting person: Bruce Polsky, Director.
- Transaction date: 20 Jun 2025; filing date 24 Jun 2025.
- Non-derivative shares: 29,600 common shares acquired at $0.00 upon RSU vesting; total direct ownership now 95,206 shares.
- New derivative grants:
- 29,600 Restricted Stock Units (RSUs) that vest on the earlier of the 2026 annual meeting or 1-year anniversary of grant.
- 41,200 stock options with a $3.25 exercise price, vesting monthly over 12 months and expiring 19 Jun 2035.
- Derivative disposition: 29,600 RSUs converted to common stock (code “M”), leaving zero balance for that award.
The filing reflects routine director equity compensation—no open-market buying or selling—and increases Mr. Polsky’s direct equity stake in AVIR. No cash outlay was required for the RSU conversion; the new option strike establishes the cost basis for potential future purchases.
Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.
- Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
- New equity awards granted:
- RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
- Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
- No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.
Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.